Related Experiment Video
Updated: Jun 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Intermediate-dose anticoagulation in COVID-19: closing the loop on a long-settled question
Behnood Bikdeli1, Alex C Spyropoulos2
1Division of Cardiovascular Medicine, Brigham and Women's Hospital, Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; YNHH/Yale Center for Outcomes Research and Evaluation, New Haven, Connecticut, USA.
No abstract available in PubMed .
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Endocarditis III: Medical Management
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction